214 related articles for article (PubMed ID: 14598082)
21. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
22. Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease.
Priano L; Albani G; Brioschi A; Calderoni S; Lopiano L; Rizzone M; Cavalli R; Gasco MR; Scaglione F; Fraschini F; Bergamasco B; Mauro A
Mov Disord; 2004 Aug; 19(8):937-42. PubMed ID: 15300660
[TBL] [Abstract][Full Text] [Related]
23. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
Marras C; Lang A; Krahn M; Tomlinson G; Naglie G;
Mov Disord; 2004 Jan; 19(1):22-8. PubMed ID: 14743356
[TBL] [Abstract][Full Text] [Related]
24. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
Zesiewicz TA; Sullivan KL; Maldonado JL; Tatum WO; Hauser RA
Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135
[TBL] [Abstract][Full Text] [Related]
25. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
[TBL] [Abstract][Full Text] [Related]
26. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
[TBL] [Abstract][Full Text] [Related]
27. Movement patterns of peak-dose levodopa-induced dyskinesias in patients with Parkinson's disease.
Gour J; Edwards R; Lemieux S; Ghassemi M; Jog M; Duval C
Brain Res Bull; 2007 Sep; 74(1-3):66-74. PubMed ID: 17683791
[TBL] [Abstract][Full Text] [Related]
28. [Early treatment of Parkinson's disease with levodopa].
Odekerken VJ; Post B; Verschuur CV; de Bie RM
Ned Tijdschr Geneeskd; 2009; 153():A286. PubMed ID: 19785822
[TBL] [Abstract][Full Text] [Related]
29. Impact of pramipexole on the onset of levodopa-related dyskinesias.
Constantinescu R; Romer M; McDermott MP; Kamp C; Kieburtz K;
Mov Disord; 2007 Jul; 22(9):1317-9. PubMed ID: 17534955
[TBL] [Abstract][Full Text] [Related]
30. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism.
Nutt JG; Woodward WR; Anderson JL
Ann Neurol; 1985 Nov; 18(5):537-43. PubMed ID: 4073849
[TBL] [Abstract][Full Text] [Related]
31. Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease.
Deleu D; Jacob P; Chand P; Sarre S; Colwell A
Neurology; 2006 Sep; 67(5):897-9. PubMed ID: 16966563
[TBL] [Abstract][Full Text] [Related]
32. Kinetic-dynamic monitoring of levetiracetam effects in patients with Parkinson disease and levodopa-induced dyskinesias.
Contin M; Martinelli P; Albani F; Scaglione C; Avoni P; Rizzo G; Baruzzi A
Clin Neuropharmacol; 2007; 30(2):122-4. PubMed ID: 17414945
[No Abstract] [Full Text] [Related]
33. Current controversies: levodopa in the treatment of Parkinson's disease.
Sharma JC; Vassallo M; Ross IN
Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129
[No Abstract] [Full Text] [Related]
34. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
[TBL] [Abstract][Full Text] [Related]
35. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
Mazzella L; Yahr MD; Marinelli L; Huang N; Moshier E; Di Rocco A
Parkinsonism Relat Disord; 2005 May; 11(3):151-5. PubMed ID: 15823479
[TBL] [Abstract][Full Text] [Related]
36. Clinical management of Parkinson's disease. Introduction.
Scheife RT
Pharmacotherapy; 1999 Nov; 19(11 Pt 2):161S. PubMed ID: 10555943
[No Abstract] [Full Text] [Related]
37. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
38. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
[TBL] [Abstract][Full Text] [Related]
39. Levodopa-related motor complications--phenomenology.
Fox SH; Lang AE
Mov Disord; 2008; 23 Suppl 3():S509-14. PubMed ID: 18781677
[TBL] [Abstract][Full Text] [Related]
40. Adenosine receptors and L-DOPA-induced dyskinesia in Parkinson's disease: potential targets for a new therapeutic approach.
Blandini F
Exp Neurol; 2003 Dec; 184(2):556-60. PubMed ID: 14769348
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
